RxDoctor Payments Data

Gleibys Sanchez

Adult Health · Pembroke Pines, FLNPI 1033621800

Payments from drug & device makers

$1,278in general payments, 2019–2025

Across 56 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$239
  • Novo Nordisk$208
  • Lilly USA, LLC$172
  • Boehringer Ingelheim$150
  • GSK$75
  • Johnson & Johnson$67
  • plus $367 from 12 others

What the payments were for

  • Food & beverage$1,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Heartflow, Inc.2$239
Novo Nordisk7$208
Lilly USA, LLC10$172
Boehringer Ingelheim7$150
GSK5$75
Johnson & Johnson4$67
Vivus LLC4$64
AbbVie4$60
Amgen2$34
Amarin Pharma, Inc.2$34
Gilead1$31
Currax Pharmaceuticals LLC2$25
Merz North America, Inc.1$23
Pfizer1$23
Exact Sciences1$20
Inogen, Inc.1$19
Bayer1$18
Aprecia Pharmaceuticals, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,278 in reported general payments places this provider in the 65th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$12,494
Medicare patients
39
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$59,163
EliquisApixaban41$51,631
OzempicSemaglutide19$33,277
JardianceEmpagliflozin19$29,300
EntrestoSacubitril/Valsartan14$22,669
FarxigaDapagliflozin Propanediol12$20,269
XareltoRivaroxaban14$17,859
Metoprolol Succinate166$2,441
Rosuvastatin Calcium252$2,187
Atorvastatin Calcium184$1,556
Losartan Potassium173$1,385
LantusInsulin Glargine,hum.Rec.Anlog14$1,346
Albuterol Sulfate HfaAlbuterol Sulfate31$1,195
Levothyroxine Sodium119$1,069
SynthroidLevothyroxine Sodium12$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$172$59,16343 claims
PfizerEliquis$23$51,63141 claims
Novo NordiskOzempic$208$33,27719 claims
Boehringer IngelheimJardiance$150$29,30019 claims
Johnson & JohnsonXarelto$67$17,85914 claims
AbbVieSynthroid$60$1,04512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,237 adult health providers in Florida.

Other adult health in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →